News
Legacy Patients From High-Dose Opioid Era
Modern pain management began to accelerate in the mid 1990’s when the fentanyl patch and extended-release oxycodone were developed and made commercially available. more info
Fentanyl Patches Overused in Vulnerable Populations
Study finds fentanyl transdermal patches are too often prescribed to opioid-naïve and elderly patients, raising their risks of fatal adverse drug events. more info
Genetic Testing in Pain Medicine—The Future Is Coming
Targeted pain therapies and screening for personality traits that may influence pain perception and addiction risk are just some of the potential promises of genetic testing in pain management. more info
DEA Ratchets Down Opioid Production
The supply of almost every Schedule II opioid manufactured in the United States will be reduced 25% or more in 2017, as required by the Drug Enforcement Administration (DEA). more info
Defining Palliative Care
Palliative care focuses on maximizing the quality of life of seriously ill patients and their families. more info
Opioid-Induced Constipation: New and Emerging Therapies—Update 2016
There has been much focus in pain management on preventing the dangerous and bothersome complications of opioid therapy, including opioid-induced constipation (OIC). more info
FDA Approves ER Hydrocodone With Abuse Deterrence Technology
The FDA has approved Vantrela ER (hydrocodone bitartrate, Teva) extended-release tablets [CII] with Teva’s proprietary abuse deterrence technology targeting oral, intranasal and IV routes. more info
FDA Approves Abuse Deterrent IR Oxycodone
The FDA has approved RoxyBond abuse-deterrent oxycodone hydrochloride tablets (RoxyBond, Inspirion) for the management of pain severe enough to require an opioid analgesic, and when alternative treatments are inadequate. more info
How to Safely Dispose of Leftover Painkillers and Other Medications
How to Safely Dispose of Leftover Painkillers and Other Medications more info